Journals / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 5

Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence

Pages
1207–1214
Publication Date
2022-09-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Drug therapy provided an effective and efficient improvement on incontinence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Urinary incontinence is defined as urinary incontinence that is a social or hygienic problem and can be objectively demonstrated.
📊
Key Findings & Data:Material and Method: Totally 98 patients, who applied to Ankara Etlik Zubeyde Hanım Gynecology Training and Research Hospital, Urogynecology Outpatient Clinic between November 2009 and October 2010 with compliants of urinary incontinence and met the criteria to participate in the research, have been included in this study.
💡
Conclusion & Impact:Drug therapy provided an effective and efficient improvement on incontinence.
🔬Design:Survey & Empirical Study
📍Scope:2009 Verileri
⚙️Variables:Pure urinary incontinence · tolterodine · trospium chloride

Abstract

Objective: Urinary incontinence is defined as urinary incontinence that is a social or hygienic problem and can be objectively demonstrated. It is aimed to compare tolterodine, trospium chloride and solifenacin treatments, and its side effects on patients who have complaints of pure urinary and mixed incontinence. Material and Method: Totally 98 patients, who applied to Ankara Etlik Zubeyde Hanım Gynecology Training and Research Hospital, Urogynecology Outpatient Clinic between November 2009 and October 2010 with compliants of urinary incontinence and met the criteria to participate in the research, have been included in this study. Results: A significant improvement in each three of the drug group at third and six months was determined. Solifenacin is generally more effective than the other two treatments. When total values of UDI-6 (Urinary Distress Inventory) survey is analysed, it is seen that each of three antimuscarinic drug group ensured improvement on symptoms at the end of the third month as not to be different from the improvement at the six month. Each three antimuscarinic drug group has a significant therapeutic effect on the IIQ-7 (Incontinence Impact Questionnaire) survey which questions the life quality. Whereas complaints of constipation was seen more at patients that use tolterodine and trospium chloride, there was not a significant difference despite a slight increase in the solifenacin group (p>0.05). It is determined that solifenacin caused desert mouth less than the other two drug groups Conclusion: Tolterodine, trospium chloride and solifenacin as anticholinergic drugs meaningfully reduced the activity of bladder and increased the quality of life. Drug therapy provided an effective and efficient improvement on incontinence.

🔖

Cite This Article

ÖZGÜRLÜK, İ., ÜNLÜBİLGİN, E., DÖLEN, İ. (2022). Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 5, 1207–1214. https://ajindex.com/articles/776436

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Abrams P, Blaivas JG, Stanton SL, et al. The standardisation of terminology of lower urinary tract function. Scand J Urol Nephrol 1988; 114: 5–18.
  2. Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess 2010; 14: 1-188.
  3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalance study. Br J Urol Int 2001; 87: 760-6.
  4. Stewart WF, Corey R, Herzog AR, et al. Prevalance overactive bladder in women: results from the Noble Program. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 66. Mills IW, Greenland JE, McMurray G, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 2000; 163: 646–51.
  5. Ghoniem GM, Walters F, Levis V. The value of vaginal pack test in large cyctoceles. J Urol 1994; 152: 931-4. Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45: 1–47.
  6. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the stadardisation sub-comittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78. Michel MC, de la Rosette JJ, Piro M, et al. Comparison of symtom severity and treatment response in patients with incontinent and overactive bladder. Eur Urol 2005; 48: 110-5.
  7. Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  8. Scheife R, Pharm D, FCCP; Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Therap 2005; 27: 144-53.
  9. Michel MC, Oelke M, Zinner N. Novel muscarinic antagonists to treat incontinence and overactive. Drug Discovery Today 2005: 1-6 Kristen Hesch. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-14.
  10. Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinerjic drugs versus plasebo for overactve bladder syndrome in adults. Cochrane Database Syst Rew 2002: 3. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients wit